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Background: Anticancer action of sodium dichloroacetate (DCA) could be related to its ability to activate oxidative phosphorylation lead-
ing to enhanced generation of reactive oxygen species and induction of apoptosis. On the other hand, activation of oxidative phosphoryla-
tion could promote tumor cell survival, in particular, via increased ATP synthesis. Such ambiguous effects of DCA could influence its 
anticancer effectiveness, depending on biological properties of a tumor, schedule of DCA administration and its dosage. The aim of the 
study was to analyze anticancer effect of DCA against glioma С6 in rats under conditions of different schedules of its administration and 
various dosages. Materials and Methods: The study was carried out in Wistar rats with intracerebrally transplanted glioma С6 cells. 
Therapy with DCA was performed as follows: daily for 6 days starting from the second day after tumor cell transplantation (schedule І) 
or 7th day (schedule ІІ) at a dose of 1.0 g/kg, or daily for 13 days starting from the second day at doses of 1.0; 1.5 or 4.5 g/kg (schedule 
ІІІ). An influence of hypoxia on anticancer effect of DCA was studied using hypoxic chambers where oxygen content was maintained 
at a level of 12.5–13% for 3 h after DCA administration to glioma С6 bearing rats. The state of mitochondrial electron transport chain 
components in tumor cells was studied using electron paramagnetic resonance. Results: It has been shown that therapy with DCA using 
schedule I resulted in 15% decrease of animals life span (LS; р < 0.05), while the use of schedule II had no effect on this index. Prolonged 
administration of DCA (schedule ІІІ) resulted in significant antitumor effect and increased LS of rats by 25.5% (p < 0.05). Under hy-
poxic conditions, treatment with DCA resulted in a significant increase of animal LS by 15–22%. Dosage of DCA had a moderate effect 
of its anticancer action. Maximal effect, an increase of LS by 34.5% (p < 0.05) was detected at a dose of 1.5 g/kg. It has been shown 
that anticancer activity of DCA under all studied conditions is not related to its influence on a functional state of tumor cell mitochondria. 
Conclusion: Anticancer effect of DCA significantly depends on a schedule of its administration; being administered at equal total dose, 
but dependent on the schedule DCA could cause ambiguous effects varying from tumor growth stimulation to significant anticancer activ-
ity. Under hypoxic conditions, anticancer efficacy of DCA against glioma С6 is significantly enhanced.
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According to statistics of World Health Organization, 
an average rate of brain tumors incidence is 10.9–12.8 per 
100 000 of population [1]. Nearly 60% of all tumors of cen-
tral nervous system are malignant neoplasmae, among 
which gliomas account up to 50–55%. By statistical 
data, gliomas yield just 1.4% from all clinically diagnosed 
tumors, but the prognosis for glioma patients is the most 
unfavorable. An average survival time of the patients 
with malignant glioma after its primary diagnosis is ap-
proximately 8 months in Ukraine and 14 months in USA [2]. 
That’s why the therapy of patients with gliomas of different 
grade of malignancy is among the most important prob-
lems of modern clinical oncology.
Despite the development of numerous novel anti-
cancer means, at present time the main approach for 
therapy of glioma patients is still a “therapy of despair”, 
i.e. surgery, but its effectiveness is insufficiently low [3, 4]. 
It is supposed that inefficiency of radical removal of glio-
mas is largely caused by tumor invasion into normal sur-
rounding tissues with the formation of indiscrete margins 
significantly reduces.
Modern protocols for radiotherapy of malignant glioma 
recommend a fractionated irradiation with low daily doses 
(> 2 Gy), with a total dose of 60–90 Gy [5]. However, even 
the modern methods of irradiation could not help to over-
come an extremely low effectiveness of the therapy, due 
to high radioresistance of glioma caused by the develop-
ment of local hypoxia [6].
Chemotherapeutics (including target agents) are 
of low effectiveness in the case of gliomas due to their 
poor bioavailability [7–10]. For example, in the majority 
of cases analysis of biopsy from malignant glioma evi-
dences on the presence of defective but functional hema-
toencephalic barrier which prevents the passage of many 
target preparations (especially antibodies against growth 
factors and receptors). For treatment of malignant glioma 
just one alkylating cytostatic preparation, temozolomide 
is used. One should note that a response to therapy with 
temozolomide could be observed just in 5–8% patients 
in the case of monotherapy, and in approximately in 20% 
patients in the case of adjuvant therapy with temozolomide 
combined with radiotherapy or surgical treatment [11, 12].
It is known that in a large part of malignant tumors ATP 
is generated via glycolysis even in the presence of oxygen 
(Warburg’s effect). Aerobic glycolysis is a low-effective 
way of ATP generation, but it supports high prolifera-
tive potential of tumor cells and promotes their survival 
decreasing the risk of formation of apoptotic stimuli [13, 
14]. Therefore, in recent years tumor metabolism, which 
provides these growth benefits, is considered as a new 
target for anticancer therapy, and compounds capable 
to inhibit glycolysis in tumor cells are studied as potentially 
effective anticancer agents [15–17]. Among antimetabolic 
agents active against many cancer cell types one could 
mention sodium dichloroacetate (DCA) [18–20].
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DCA inhibits pyruvate dehydrogenase kinase (PDH) 
that results in indirect activation of enzymes of PDH com-
plex and consequently in a shift of cell metabolism from 
glycolysis toward oxidative phosphorylation. In a case 
of activation of oxidative phosphorylation and decreased 
intensity of glycolysis upon DCA action, one could expect 
an inhibition of tumor cell proliferation caused, in particu-
lar, by significant decrease of the content of metabolites 
of pentose-phosphate bypass and pyruvate important for 
synthesis of proteins and nucleic acids. DCA-induced ac-
tivation of mitochondrial metabolism may lead to  blocking 
of tumor cell proliferation and enhancement of reactive 
oxy gen species (ROS) generation and apoptosis induc-
tion. However, despite theoretic apparentness of anti-
cancer action of DCA, its effectiveness is not guaranteed. 
As it has been shown [21], at a wide concentration range 
DCA exerts cytostatic but not cytotoxic action, what is sup-
ported by the data on an absence of its effect toward 
intracellular level of ROS, the rate of lactate production 
and apoptosis rate in glioma С6 cells.
In addition, it is necessary to note that DCA-induced 
activation of oxidative phosphorylation may result not 
only in anticancer effect but also may promote tumor cell 
survival via increased ATP synthesis. Such ambivalent 
influence on tumor cell survival predisposes a variability 
of DCA activity [22, 23]. Biologic properties of a tumor, 
schedules of DCA administration and its doses could 
significantly affect its anticancer effectiveness.
The aim of the study was to analyze anticancer effec-
tiveness of DCA against glioma С6 in rats under conditions 
of different schedules of its administration and dosing.
MATERIALS AND METHODS
The study was performed in female Wistar rats 
2.5–3 months old weighting 90–150 g, bred at animal 
facility of R.E. Kavetsky Institute of Experimental Patho-
logy, Oncology and Radiobiology of the National Academy 
of Sciences of Ukraine (IEPOR). The use and care of the 
experimental animals have been performed in accordance 
with the standard international rules of biologic ethics and 
was approved by Institutional Animal Care and Use Com-
mittee. Glioma С6 cell line was obtained from the National 
Bank of Cell Lines and Tumor Strains of IEPOR.
Glioma С6 cells were cultured in vitro in DMEM 
culture medium supplemented with 10% FBS (Sigma, 
USA), 2 mM L-glutamine, and 40 mg/ml gentamycin 
at 37 °С in humidified atmosphere with 5% СО2. Trans-
plantation of glioma С6 cells was performed under total 
anesthesia via intracerebral inoculation of 0.6•106 cells 
in 0.05 ml of physiologic solution in a left parietal area 
(anterior horn of left lateral ventricle).
Aqueous DCA solution (Sigma-Aldrich, USA) was 
administered daily per os through a tube in a volume 
of 3 ml per animal. Therapy with DCA was performed 
by different schedules and at different doses as follows:
•	schedule І — DCA was administered daily for 6 days 
starting from the second day after tumor cell trans-
plantation at a total dose of 1.0 g/kg;
•	schedule ІІ — DCA was administered daily for 6 days 
starting from the 7th day after tumor cell transplantation 
at a total dose of 1.0 g/kg;
•	schedule ІІІ — DCA was administered daily for 13 days 
starting from the second day at total doses of 1.0; 
1.5 or 4.5 g/kg.
All animals from corresponding control groups received 
3.0 ml of water for injections by the schedules for DCA 
administration. There were 13–15 rats per each group.
At day 14 after tumor cell inoculation 4–5 rats from each 
group were sacrificed under ether narcosis, blood was 
collected; brain tissue was taken for further examination.
The changes in survival time (CST) of remaining ani-
mals served as an index of anticancer effect of the treat-
ment calculated by a formula:
CST (%) = 100 • (ST – STC)/STC,
where ST and STС are survival time of rats from experimen-
tal and control groups, respectively.
An influence of hypoxia (inhibitor of oxidative phos-
phorylation) on anticancer effect of DCA was studied using 
hypoxic chambers where oxygen content was maintained 
at a level of 12.5–13% for 3 h after DCA administration 
to glioma С6 bearing rats. Content of oxygen in hypoxic 
chambers was controlled using oxymeter ISO2 (World 
Precision Instruments, USA). Anticancer effects of the 
treatment were evaluated by prolongation of survival time 
of animals with glioma С6.
The changes of the state of mitochondrial electron 
transport chain (MtETC) components in tumor cells were 
analyzed using the method of electron paramagnetic reso-
nance. Electron paramagnetic resonance (EPR)-analysis 
of the samples was performed at 77 К using spectro-
photometer Е-109 Varian (USA). By the data of EPR 
spectroscopy, the levels of reduced non-heme iron-sulfur 
(Fe-S) centers (g = 1.94) of MtETC proteins, nitrosyl (NO) 
complexes of heme iron (gсер = 2.01) and Fe-S nitrosyl 
complexes (gсер = 2.03) were determined.
Statistical analysis of the data was performed by de-
scriptive methods, correlation analysis, non-linear re-
gression analysis, Student’s t-test, and Mann — Whitney 
U test, with the use of Microsoft Excel, Microcal Origin and 
Statistica. The data are presented as M ± m.
RESULTS AND DISCUSSION
The results of the study have shown that an effective-
ness of DCA against glioma С6 depends on admini stration 
schedule and is significantly increased if the animals are 
kept under hypoxic conditions for 3 h after administration 
of this agent.
As one may see (Table 1), therapy with DCA by sche-
dule I resulted in 15% decrease of animals life span (LS; 
р < 0.05). Upon application of schedule II which differs 
from schedule I by later terms of treatment initiation, 
no effect on LS of experimental animals was observed. 
Prolonged administration of DCA (schedule ІІІ) resulted 
in significant antitumor effect and increased LS of rats 
by 25.5% (p < 0.05).
Usually in preclinical trials an effectiveness of antican-
cer agents administration of which begins at the back-
ground of an already developed tumor (days 7–10 after 
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tumor cell inoculation), is lower compared with that if such 
agents are administered at earlier terms (day 2 after tumor 
cell inoculation). However, our data have demonstrated 
an opposite picture: an efficacy of DCA is higher against 
a developed tumor. It is known that a developed tumor 
is characterized by the development of intratumoral hy-
poxia. An increase of LS of rats with glioma С6 after pro-
longed administration of DCA at the background of a de-
veloped tumor could be related with the deve lopment 
of intratumoral hypoxia as far as DCA-induced activation 
of oxidative phosphorylation under conditions of oxygen 
deficiency significantly decreases ATP synthesis and, con-
sequently, may result in tumor cell death. This assumption 
is in agreement with the results of the study that analyzed 
an influence of hypoxia on an effectiveness of cytotoxic/
cytostatic action of DCA against glioma С6 cells in vitro. 
As it has been shown [21], significant enhancement 
of cytotoxic action of DCA against glioma С6 cells under 
hypoxic conditions (triple decrease of DCA IC50 vs that 
under normoxic conditions of culturing) was determined 
by high-level DCA-induced necrosis of the cells.
Administration of DCA under hypoxic conditions 
resulted in significant increase of its anticancer effect. 
In particular, in the case of schedule I DCA administra-
tion under hypoxic conditions had no effect on LS of ex-
perimental animals while in an absence of hypoxia such 
therapy stimulated tumor process and caused 15% 
reduction of LS. Being administered by sche dule II under 
hypoxic conditions, DCA significantly prolonged LS of rats 
by 22% compared to the animals treated with DCA under 
conditions of normoxia (Table 1). However, it is neces-
sary to note that significant variability of antiglioma action 
of DCA upon different schedules of its administration was 
observed under conditions of hypoxia as well as normoxia.
Table 1. Anticancer effectiveness of DCA administered by different schedules 
under conditions of normoxia and hypoxia
Type of therapy
Schedule of DCA administration Change 
of LS, %Number
Beginning 
(day)
Duration of treat-
ment (days)
DCA І 2nd 6 −15.0
ІІ 7th 6 0.0
ІІІ 2nd 13 +25.5
DCA + hypoxia І 2nd 6 0.0
ІІ 7th 6 +22.0
Among possible mechanisms of anticancer action 
of inhibitors of energetic metabolism of tumor cells, in-
cluding DCA, one could mention an ability of these agents 
to exert a damaging effect on a functional state of MtETC 
in tumor cells through activation of oxidative phosphoryla-
tion, hypoxia and possible defectiveness of mitochondrial 
system. That’s why we have studied an influence of DCA 
on a functional state of MtETC using EPR spectroscopy.
High invasiveness of glioma complicates an accurate 
separation of tumor and normal tissues. That’s why for 
preparation of EPR samples we have used the tissue 
of cerebral hemisphere with the tumor, and for a compari-
son — the tissue of cerebral hemisphere without tumor.
As indexes of functional state of MtETC we have used 
the levels of NO complexes of mitochondrial heme iron 
(that reflects a damaging action of ROS and nitrogen 
toward ETC), and the content of Fe-S centers, directly 
reflecting a functional state of this energetic system.
An analysis of DCA effects under conditions of nor-
moxia and hypoxia on a functional state of MtETC in glioma 
С6 cells revealed an absence of correlation between 
MtETC functionality and LS of experimental animals 
(Table 2).
As shown in Table 2, administration of DCA by all 
schedules under conditions of normoxia and hypoxia 
had no effect on the levels of Fe-S centers in cerebral 
hemisphere with glioma С6 even at the background 
of significant (more than 46.7%) increase of nitrosylation 
level of heme proteins registered after DCA adminis-
tration under normoxic conditions. It is supposed that 
a decrease of the content of Fe-S centers in tumor tissue 
characterizes a malfunction of MtETC resulting in tumor 
cell death. Unchanged content of Fe-S centers indicated 
that anticancer action of DCA is not related to its influence 
on a functional state of mitochondria in glioma С6 cells.
Table 2. Influence of DCA administered by different schedules under conditions 
of normoxia and hypoxia on the indexes of a functional state of MtETC in the cells 
of cerebral hemisphere with glioma
Group of animals Cerebral hemisphere with gliomaSchedule І Schedule ІІ Schedule ІІІ
Intensity of EPR signal for NO-heme complexes (g = 2.01; a.u.)
Control 100.0 ± 2.9 100.0 ± 6.5 100.0 ± 1.4
DCA 153.1 ± 21.7* 146.7 ± 13.0* 152.4 ± 20.8*
DCA + hypoxia 87.4 ± 14.3 148.4 ± 9.8* 103.6 ± 10.7
Intensity of EPR signal for Fe-S centers (g=1.94; a.u.)
Control 100.0 ± 40.4 100.0 ± 19.1 100.0 ± 28.9
DCA 97.5 ± 17.4 112.4 ± 23.0 83.3 ± 19.2
DCA + hypoxia 100.6 ± 37.3 115.1 ± 40.0 108.3 ± 16.0
Note: *p < 0.05, differences are significant as compared to the value for control.
Contrary to the brain tissue samples with glioma, the 
content of NO-heme complexes in normal brain tissue 
after DCA administration by schedules І and ІІІ significantly 
decreased by more than 17% under conditions of normo-
xia and hypoxia (Table 3). However, the level of Fe-S cen-
ters in normal brain tissue remained unaltered.
Table 3. Influence of DCA administered by different schedules under conditions 
of normoxia and hypoxia on the indexes of functional state of MtETC in the cells 
cerebral hemisphere without glioma
Group of animals Cerebral hemisphere without gliomaSchedule І Schedule ІІ Schedule ІІІ
Intensity of EPR signal for NO-heme complexes (g = 2.01; a.u.)
Control 100.0 ± 3.4 100.0 ± 4.3 100.0 ± 2.7
DCA 82.8 ± 3.4* 119.6 ± 2.9* 82.9 ± 3.6*
DCA + hypoxia 72.1 ± 9.9* 123.0 ± 9.1 56.8 ± 20.4*
Intensity of EPR signal for Fe-S centers (g = 1.94; a.u.)
Control 100.0 ± 34.0 100.0 ± 5.3 100.0 ± 20.0
DCA 129.0 ± 37.7 103.2 ± 23.8 101.3 ± 28.1
DCA + hypoxia 109.9 ± 17.3 105.3 ± 21.2 104.0 ± 19.0
Note: *p < 0.05, differences are significant as compared to the value for control.
The study of effects of DCA dosing on LS of rats was 
done by the schedule with the highest anticancer ef-
ficacy. It has been shown that DCA dose moderately af-
fected an efficacy of its antiglioma action (Figure, Table 4). 
The maximal effect was registered if DCA was adminis-
tered at a dose of 1.5 g/kg: LS of experimental animals 
increased by 34.5% (p < 0.05). An elevation of DCA dose 
up to 4.5 g/kg did not lead to the further rise of its efficacy: 
the LS of rats was significantly higher than that in control 
animals not treated with DCA, but didn’t differ from that 
in animals treated with a dose of 1.0 g/kg.
An analysis of DCA effects upon its prolonged ad-
ministration at different doses did not reveal significant 
changes in the nitrosylation levels of heme proteins and 
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content of Fe-S centers in the cells of cerebral hemi-
sphere with glioma (Table 5), and normal brain tissue 
(Table 6).
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Figure. Survival curves of rats with glioma С6 treated with DCA 
administered at different doses by schedule III
Table 4. Dependence between DCA dosing and its antiglioma effectiveness
Total dose, 
g/kg
Schedule of ad-
ministration
Beginning 
(day)
Duration of ther-
apy (days)
Change of LS, 
%
1.0 III 2nd 13 +25.5
1.5 III 2nd 13 +34.5
Table 5. Effects of DCA administered at different doses on the indexes 
of a functional state of MtETC in the cells of cerebral hemisphere with glioma
Group of animals Cerebral hemisphere with gliomaDІ D2 D3
Intensity of EPR signal for NO-heme complexes (g = 2.01; a.u.)
Control 100.0 ± 1.4 100.0 ± 3.5 100.0 ± 3.5
DCA 152.4 ± 20.8* 93.1 ± 13.0 103.0 ± 3.1
Intensity of EPR signal for Fe-S centers (g=1.94; a.u.)
Control 100.0 ± 28.9 100.0 ± 5.5 100.0 ± 5.5
DCA 83.3 ± 19.2 88.1 ± 12.1 101.2 ± 10.6
Note: *p < 0.05, differences are significant as compared to the value for control.
Table 6. Effects of DCA administered at different doses on the indexes 
of a functional state of MtETC in the cells of cerebral hemisphere without glioma
Group of animals Cerebral hemisphere without gliomaDІ D2 D3
Intensity of EPR signal for NO-heme complexes (g = 2.01; a.u.)
Control 100.0 ± 2.7 100.0 ± 13.0 100.0 ± 13.0
DCA 82.9 ± 3.6* 94.2 ± 2.7 79.4 ± 5.4
Intensity of EPR signal for Fe-S centers (g = 1.94; a.u.)
Control 100.0 ± 20.0 100.0 ± 15.5 100.0 ± 15.5
DCA 101.3 ± 28.1 118.6 ± 3.6 102.4 ± 6.9
Note: *p < 0.05, differences are significant as compared to the value for control.
An absence of such changes along with a high anti-
cancer efficacy of DCA (especially at a dose of 1.5 g/kg) 
once more demonstrated that effects of DCA against 
glioma С6 have no relation to a functional state of tumor 
cell mitochondria.
In conclusion, the results of our study have shown that 
anticancer effectiveness of DCA significantly depends 
on the schedule of its administration whereupon it varies 
from a significant decrease of LS directly correlating with 
stimulation of tumor growth, to significant anticancer ef-
fect and increased LS of rats by 25.5%. Prolonged met-
ronomic administration of DCA provides better anticancer 
effectiveness with low variability between the doses. Also, 
it has been demonstrated that hypoxic conditions of ani-
mal keeping significantly elevate an antiglioma efficacy 
of DCA. Along with this, anticancer activity of this agent 
is not related to its effects on a functional state of tumor 
cell mitochondria.
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